GRAIL Reports Third Quarter 2026 Financial Results
PR Newswire•04/11/2026•16:02 ET
0
Key Highlights
- ➤FDA advisory committee voted in favor of Galleri approval; decision anticipated by early Q1 2027
- ➤Q3 Galleri revenue $37.3 million, up 14% year-over-year
- ➤Q3 Galleri test volume exceeded 56,000, up approximately 24% year-over-year
- ➤Q3 net loss $103.6 million, up 16% year-over-year
- ➤Cash, equivalents, and short-term securities totaled $788.7 million at September 30
Expert Statements
Josh Ofman, Chief Executive Officer of GRAIL
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee,”
Josh Ofman, Chief Executive Officer of GRAIL
“This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement.”
Josh Ofman, Chief Executive Officer of GRAIL
“We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”
GRAIL Reports Third Quarter 2026 Financial Results PR Newswire
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test
Get started
Create a free account to read the full story.